The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. Viking Therapeutics and ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President ...

According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...